收藏切换
Comparative Effectiveness and Safety of Edaravone Dexborneol Versus Edaravone in Acute Ischemic Stroke: Meta Analysis
收藏切换
Weidan ZHONG1, 2, Ke ZHONG1, Zhichao HE1, Jianhong ZHU1, Junyan WU1, *
Pharmacy Today | 2026, 36(1) : 41 - 48
Less
收藏切换
Pharmacy Today | 2026, 36(1): 41-48
Comparative Effectiveness and Safety of Edaravone Dexborneol Versus Edaravone in Acute Ischemic Stroke: Meta Analysis
Full
Weidan ZHONG1, 2, Ke ZHONG1, Zhichao HE1, Jianhong ZHU1, Junyan WU1, *
Affiliations
  • 1.Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510120, China
  • 2.School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong 523808, China
Published: 2026-01-25 doi: 10.12048/j.issn.1674-229X.2026.01.008
Outline
收藏切换
OBJECTIVE

To compare the efficacy and safety differences between edaravone dexborneol and edaravone in Acute ischemic stroke (AIS).

METHODS

Randomized controlled trials (RCTs) of edaravone dexborneol versus edaravone in the treatment of AIS were identified by systematically searching PubMed, Embase, Cochrane Library, CNKI, VIP Database, Wanfang Data, and SinoMed. The risk of bias of included studies was assessed according to the Cochrane bias risk assessment tool, and meta-analysis was performed using R 4.4.1 and RevMan 5.3. The efficacy outcomes included changes from baseline in the National Institutes of Health Stroke Scale (NIHSS) scores, the Modified Rankin Scale (mRS) scores, the Barthel Index (BI), and clinical response rate at 14 days post-treatment. Adverse reactions occurring during treatment were considered as safety indicators.

RESULTS

A total of 19 studies involving 2 885 patients were ultimately included. After 14 days of treatment, compared with the edaravone group, the edaravone dexborneol group was more effective in improving the clinical response rate [RR =1.22, 95%CI =1.13-1.33, P < 0.000 1] and the BI [MD =10.60, 95%CI =8.12-13.07, P < 0.000 1], and in reducing the NIHSS [MD =-1.92, 95%CI = -2.61-1.23, P < 0.000 1] and mRS [MD = 1.69, 95%CI = -2.49--0.90, P < 0.000 1]. In terms of safety, edaravone dexborneol group had a lower incidence of adverse reactions during the treatment period than the edaravone group [RR =0.47, 95%CI =0.33-0.69, P < 0.000 1].

CONCLUSION

Edaravone dexborneol group exhibited superior efficacy and safety compared with edaravone group in the treatment of AIS.

edaravone dexborneol  /  edaravone  /  acute ischemic stroke (AIS)  /  Meta-analysis
钟伟丹, 钟科, 何志超, 朱建红, 伍俊妍. 依达拉奉与依达拉奉右莰醇治疗急性缺血性脑卒中的疗效与安全性比较:Meta分析. 今日药学, 2026 , 36 (1) : 41 -48 . DOI: 10.12048/j.issn.1674-229X.2026.01.008
Weidan ZHONG, Ke ZHONG, Zhichao HE, Jianhong ZHU, Junyan WU. Comparative Effectiveness and Safety of Edaravone Dexborneol Versus Edaravone in Acute Ischemic Stroke: Meta Analysis[J]. Pharmacy Today, 2026 , 36 (1) : 41 -48 . DOI: 10.12048/j.issn.1674-229X.2026.01.008
Year 2026 volume 36 Issue 1
137
32
Cite this Article
BibTeX
Article Info
doi: 10.12048/j.issn.1674-229X.2026.01.008
  • Receive Date:2025-03-24
  • Online Date:2026-09-23
  • Published:2026-01-25
Article Data
Affiliations
History
  • Received:2025-03-24
Funding
Affiliations
    1.Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510120, China
    2.School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong 523808, China
References
Share
https://castjournals.cast.org.cn/joweb/jryx/EN/10.12048/j.issn.1674-229X.2026.01.008
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT